Ir-CPI displays an antithrombotic activity through its interaction with upstream blood coagulation factors (FXIa/FXIIa) of the intrinsic pathway.
Bioxodes has also demonstrated that Ir-CPI decreases neutrophil activation and Neutrophil Extracellular Trap (NET) release. Neutrophils and NETs, networks of extracellular fibers primarily constituted of DNA, are known to be involved in thrombo-inflammatory and inflammatory diseases (e.g. stroke, rheumatoid arthritis, lupus, sepsis).
Due to its outstanding dual mechanism of action on both coagulation factors and neutrophils, Ir-CPI not only prevents thrombo-inflammatory processes but also represents a promising alternative to current anticoagulants as deficiencies in FXII and FXI protect against thrombosis without causing spontaneous hemorrhage.